Clinical heterogeneity is a hallmark of psychosis, with variation in symptom presentation,
neurocognitive function and treatment response. To date, few biological markers reliably
differentiate between dimensions characterizing the disorder. Molecular genetic approaches
may identify such biomarkers as they can be assessed in large populations, whereas
neuroimaging provides detailed information on brain function.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2020 Published by Elsevier Inc.
